The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Treatment challenges in the age of immunotherapy
Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, shares some insights into the challenges associated with myeloma treatment in the age of novel immunotherapies. Prof. Lonial first comments on the variety of immunotherapies that exist for patients with myeloma, including bispecific antibodies, CAR-T cells, and antibody-drug conjugates (ADCs). Prof. Lonial then explains the need to decide which agents to combine and when to use different classes of agents to provide patients with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
